Latanoprost
Rank #171 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$92.3M
Total Cost
4,388,601
Total Claims
$92.3M
Total Cost
30,521
Prescribers
$21
Cost per Claim
1,123,409
Beneficiaries
8,081,496
30-Day Fills
$3,024
Avg Cost/Provider
144
Avg Claims/Provider
Share of Medicare Part D Spending
0.03%
of total Medicare Part D spending
$92.3M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $92.3M total
Top Prescribers of Latanoprost
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Kundandeep Nagi | Ophthalmology | San Antonio, TX | 3,812 | $140K |
| 2 | Deborah Alexander | Ophthalmology | Weslaco, TX | 4,328 | $132K |
| 3 | Barbara Marsh | Ophthalmology | Albuquerque, NM | 3,439 | $121K |
| 4 | John Aey | Ophthalmology | Youngstown, OH | 3,628 | $104K |
| 5 | Carlton Haley | Ophthalmology | Garland, TX | 2,548 | $102K |
| 6 | Michael Yoon | Ophthalmology | Banning, CA | 2,959 | $97K |
| 7 | Sarah Anis | Ophthalmology | Providence, RI | 3,450 | $92K |
| 8 | Jeffrey Levenson | Ophthalmology | Jacksonville, FL | 3,033 | $90K |
| 9 | Jacob Moore | Ophthalmology | Corpus Christi, TX | 3,064 | $89K |
| 10 | Frank Mares | Ophthalmology | Albuquerque, NM | 2,901 | $87K |
| 11 | Michael Pohlod | Ophthalmology | Orlando, FL | 3,178 | $85K |
| 12 | Unni Nair | Ophthalmology | Fort Worth, TX | 2,790 | $84K |
| 13 | Thomas Dietze | Ophthalmology | Corpus Christi, TX | 3,950 | $83K |
| 14 | John Gooch | Ophthalmology | The Villages, FL | 1,833 | $81K |
| 15 | Sarah Escott | Ophthalmology | Morganton, NC | 2,303 | $79K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 168 | Aripiprazole Lauroxil (Aristada) | $93.3M | 31,120 |
| 169 | Trazodone Hcl (Trazodone Hcl) | $92.6M | 7,273,528 |
| 170 | Insulin Glargine/Lixisenatide (Soliqua 100-33) | $92.5M | 82,886 |
| 171 | Latanoprost (Latanoprost) | $92.3M | 4,388,601 |
| 172 | Ribociclib Succinate (Kisqali) | $90.3M | 5,978 |
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
| 174 | Mepolizumab (Nucala) | $90.1M | 20,798 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology